Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Perigon Wealth Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the SEC. The firm bought 7,164 shares of the biopharmaceutical company’s stock, valued at approximately $4,467,000.

Several other hedge funds have also bought and sold shares of REGN. Insigneo Advisory Services LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares in the last quarter. Arjuna Capital boosted its holdings in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares during the period. Finally, MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. HSBC lowered their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of REGN stock opened at $805.93 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The company’s fifty day simple moving average is $679.69 and its two-hundred day simple moving average is $714.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock has a market capitalization of $82.98 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.37 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $12.81 EPS. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.